VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration.

被引：0
|
作者：
Yamamoto, K. [1 ]
Kuwahara, M. [1 ]
Yamamoto, S. [1 ]
机构：
[1] Int Univ Hlth & Welf, Med Kouhoukai Takagi Hosp, Thorac Surg, Ohkawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
VATS right upper lobectomy; ALK-tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P84.20
引用
收藏
页码：S666 / S667
页数：2
相关论文
共 50 条
  • [1] Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.
    Yabe, Michitoshi
    Kenmotsu, Hirotsugu
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Eriko
    Miyawaki, Taichi
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Comparison of complete VATS lobectomy and hybrid VATS lobectomy for non-small cell lung cancer
    Tsunezuka, Yoshio
    Yachi, Tsuyoshi
    Waseda, Ryuichi
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S573 - S573
  • [3] Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments
    Le, H.
    Coulter, J.
    Cappelleri, J. C.
    Lu, H.
    Quaife, M.
    Meginnis, K.
    Fernandez, G.
    Culver, K.
    Vaghela, S.
    Rifi, N.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S202 - S202
  • [4] Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment
    Ohtaki, Yoichi
    Shimizu, Kimihiro
    Suzuki, Hiroyuki
    Suzuki, Kenji
    Tsuboi, Masahiro
    Mitsudomi, Tetsuya
    Takao, Motoshi
    Murakawa, Tomohiro
    Ito, Hiroyuki
    Yoshimura, Kenichi
    Okada, Morihito
    Chida, Masayuki
    LUNG CANCER, 2021, 153 : 108 - 116
  • [5] Is VATS lobectomy standard of care for operable non-small cell lung cancer?
    Vannucci, Fernando
    Gonzalez-Rivas, Diego
    LUNG CANCER, 2016, 100 : 114 - 119
  • [6] VATS LOBECTOMY FOR NON-SMALL CELL LUNG CANCER IN PATIENTS WITH SEVERE COPD
    Wang, Wei
    Xu, Zhiqiang
    Xiong, Xinguo
    Yin, Weiqiang
    Shao, Wenlong
    Xu, Xin
    Chen, Hanzhang
    He, Jianxing
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S518 - S518
  • [7] Salvage surgery following tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer
    Kobayashi, Masao
    Funaki, Soichiro
    Nagata, Hideki
    Furukawa, Mitsugi
    Morii, Eiichi
    Shintani, Yasushi
    SURGICAL CASE REPORTS, 2024, 10 (01):
  • [8] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [9] AN INCREMENTAL EFFECTIVENESS ANALYSIS OF LORLATINIB FOR THE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER THAT HAS PROGRESSED AFTER ANOTHER ALK TYROSINE KINASE INHIBITOR IN PORTUGAL
    Guerreiro, R.
    Paquete, A. T.
    Iadeluca, L.
    Almond, C.
    Albuquerque de Almeida, F.
    Ines, M.
    Costa, J.
    Borges, M.
    Silva Miguel, L.
    VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [10] ECONOMIC ANALYSIS OF THE USE OF CRIZOTINIB, A TYROSINE KINASE ALK INHIBITOR, IN THE TREATMENT OF ALK POSITIVE NON-SMALL CELL LUNG CANCER IN THE MEXICAN SETTING
    Gay-Molina, J. G.
    Sanchez-Kobashi, R.
    Mucino-Ortega, E.
    Gutierrez-Coln, C., I
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2012, 15 (07) : A422 - A422
12345